Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma
jRCT2080222800Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab + ipilimumab with Sunitinib (2 arms). Started Mar 2015; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080222800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222800.